Compare SCTX & DRDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCTX | DRDB |
|---|---|---|
| Founded | 2017 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.2M | 326.9M |
| IPO Year | 2026 | 2024 |
| Metric | SCTX | DRDB |
|---|---|---|
| Price | $16.15 | $10.79 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $57.00 | N/A |
| AVG Volume (30 Days) | ★ 346.2K | 51.2K |
| Earning Date | 11-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $597.54 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.50 | $10.42 |
| 52 Week High | $39.60 | $10.79 |
| Indicator | SCTX | DRDB |
|---|---|---|
| Relative Strength Index (RSI) | 43.27 | 63.09 |
| Support Level | $13.90 | $10.50 |
| Resistance Level | $22.07 | N/A |
| Average True Range (ATR) | 1.58 | 0.01 |
| MACD | 0.33 | 0.00 |
| Stochastic Oscillator | 52.49 | 100.00 |
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
Roman DBDR Acquisition Corp II is a blank check company.